Doris Hansen, MD, discusses the promise of ALLO-715 in relapsed/refractory multiple myeloma. Scroll to 0:07 in the video for Dr. Hansen's topline points on the agent.
ALLO-715 is a novel CAR T-cell therapy directed toward BCMA. Unlike autologous CAR T-cell therapies, ALLO-715 is an allogeneic, off-the-shelf product that has the potential to mitigate manufacturing challenges encountered with the autologous approach, Hansen explains.
Furthermore, many patients with relapsed/refractory multiple myeloma experience disease progression during the period required for autologous CAR T-cell therapy generation. With ALLO-715, patients can receive their infusion within a period of 5 days, Hansen says.
Initial findings from the ongoing phase 1 UNIVERSAL trial (NCT04093596) demonstrated an overall response rate of 60% with a 320 x 106 dose of CAR cells in 6 patients with relapsed/refractory multiple myeloma. Four patients treated at this dose level achieved at least a very good partial response and minimal residual disease negativity.
On April 21, 2021, the FDA granted ALLO-715 a Regenerative Medicine Advanced Therapy designation as a potential treatment for patients with relapsed/refractory multiple myeloma.